胰腺癌的新药治疗.pptVIP

New Drugs in Pancreatic Cancer Agenda Current situation. Promising new targets. Approaches to new drug development The “omis” of pancreatic cancer. Significant Problem Pivotal Phase III Study of Gemcitabine in Pancreatic Cancer Pivotal Phase III Study of Gemcitabine in Advanced Pancreatic Cancer Most Common Strategies to Develop Drug A in Pancreas Cancer Drug Tested that Failed Taxanes. Topo I inhibitors. Platinum analogs. FTIs. VEGF antibodies. MMP. EGFR antibodies. Antimetabolites. Supervivencia Global Laboratory Abnormalities PA.3: Riesgo relativo en supervivencia con características basales (100mg cohorte) PA.3: Supervivencia global en pacientes con Cáncer de Páncreas metastásico* PA.3 Rash vs Supervivencia Punch line of Erlotinib in Pancreatic Cancer Another drug for docs and patients to use. Data is weak but still best data. Need to continue exploring erlotinib in pancreas cancer: Adjuvant and neoadjuvant settings. Continue to explore biomarkers of activity. Exploit rash as a predictor of efficacy. Incorporate into other combinations Factors that may be implicated in high failure rate Few single agent studies. Most studies have been done in combination with gemcitabine. Poor understanding of mechanism of action. MMPs Ras inhibitors. Lack of solid phase II data. Cetuximab. Mitomycin C - Sensitivity Poly (ADP-Ribose) Polymerase Pathway PARP Inhibitors Some Recently Discovered Potential Targets in Pancreatic Cancer Targeting Hedgehog Pathway in Pancreatic Cancer Newer Approaches for Drug Development in Pancreatic Cancer Better understanding of what are the key targets. Drug development oriented preclinical models. More effective clinical trials design. Gene Genetic Mouse Models of Pancreas Cancer The Complexity of Cancer Genome The “omics” of pancreatic Gene mutations. Gene deletions and amplifications: CGH, MLPA, SNP analysis. Expression arrays. microRNAs. Methylation. Proteomics. More to come. MLPA Assessment of Gene Changes in the EGFR Pathway KEGG Active